BioSpace News Archive

The integration of the sequence of each single cell coupled with IsoPlexis’ proprietary functional proteomics accelerates insights into discovery biology & development of advanced medicines

UroGen Pharma Ltd., a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, announced that it will present at the following virtual conferences in June

Biotricity, Inc. , a medical diagnostic and consumer healthcare technology company, is pleased to announce that it has begun executing on its strategy towards an uplist to a National Exchange in 2021. Waqaas Al-Siddiq, CEO of Biotricity previously mentioned this as a top priority for 2021.

Digital health leader, physIQ Inc. , recently announced that Intermountain Healthcare Utah , The University of Texas Health Science Center at Houston (UTHealth) and Rush University Medical Center have joined the NIH-funded DeCODe study to develop an AI-based COVID-19 digital biomarker. These institutions will serve as recruiting centers and key partners in the Phase II validation stage of this study.

Expansion Therapeutics, Inc., a biotechnology company advancing transformative medicines to patients with RNA-mediated diseases, today announced the in-licensing of two new research programs from Scripps Research. One program targets tau, a key driver of dementia disorders

Primary endpoint of non-inferior immunogenicity versus the Phase 3 study adult comparator group was met No cases of COVID-19 observed after two doses of vaccine using the primary case definition, consistent with a vaccine efficacy of 100% Safety and tolerability generally consistent with Phase 3 COVE study in adults; no significant safety concerns identified

Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning (ML), and engineering, today announced the company has initiated investigational new drug (IND)-enabling studies for REC-163964

Quotient Limited, a commercial-stage diagnostics company, announced that financial results for its fiscal fourth quarter and full year ended March 31, 2021 will be released before market open on Tuesday, June 1, 2021.

One hundred generous supporters of St. Jude Children’s Research Hospital® raised $900,000 for the kids of St. Jude at this year’s Legends for Charity®Dinner, which took place on May 15 at the Tampa home of event co-chairs Drew and Morgan Weatherford.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Dion Neame has joined the company’s Strategic Advisory Board (SAB).